Breaking News, Collaborations & Alliances

Novelty Nobility Expands Manufacturing Pact With AGC Biologics in Japan

The partnership will work to advance Novelty Nobility’s bispecific antibody drug candidate through process development and GMP manufacturing.

Author Image

By: Patrick Lavery

Content Marketing Editor

Novelty Nobility is expanding a manufacturing agreement with AGC Biologics to advance a bispecific antibody drug candidate in Japan. The candidate will progress through process development and good manufacturing practice (GMP) manufacturing at AGC Biologics’ facility in Chiba, Japan. AGC Biologics defines itself as a global pharmaceutical CDMO. Meanwhile, Novelty Nobility, based in South Korea, is a clinical stage biotechnology company. The agreement continues a partnership begun in May 20...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters